{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:41:24Z","timestamp":1791884484912,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Focal segmental glomerulosclerosis (FSGS) causes renal fibrosis and may lead to kidney failure. FSGS and its common complication, proteinuria, are challenging to treat. Corticosteroids are ineffective in many patients with FSGS, and alternative treatments often yield suboptimal responses. Repository corticotropin injection (RCI; Acthar\u00ae Gel), a naturally sourced complex mixture of purified adrenocorticotropic hormone analogs and other pituitary peptides, may have beneficial effects on idiopathic FSGS via melanocortin receptor activation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two studies in a preclinical (female Sprague-Dawley rats) puromycin aminonucleoside FSGS model assessed the effect of RCI on renal function and morphology: an 8-week comparison of a single RCI dose with methylprednisolone (<jats:italic>N<\/jats:italic>\u2009=\u200927), and a 12-week chronic RCI dose range study (<jats:italic>N<\/jats:italic>\u2009=\u200934). Primary outcomes were proteinuria and renal pathology improvements for measures of renal fibrosis, tubular damage, glomerular injury, and total kidney injury score. Impact of RCI treatment was also determined by assessing urinary biomarkers for renal injury, podocyte expression of podoplanin (a biomarker for injury), podocyte effacement by electron microscopy, and histological staining for fibrosis biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with saline treatment, RCI 30\u2009IU\/kg significantly reduced proteinuria, with a 38% reduction in peak mean urine protein levels on day 28 in the 8-week model, and RCI 10\u2009IU\/kg, 30\u2009IU\/kg, and 60\u2009IU\/kg reduced peak mean urine protein in the 12-week model by 18, 47, and 44%, respectively. RCI also showed significant dose-dependent improvements in fibrosis, interstitial inflammation, tubular injury, and glomerular changes. Total kidney injury score (calculated from histopathological evaluations) demonstrated statistically significant improvements with RCI 30\u2009IU\/kg in the 8-week study and RCI 60\u2009IU\/kg in the 12-week study. RCI treatment improved levels of urinary biomarkers of kidney injury (KIM-1 and OPN), expression of podoplanin, and podocyte morphology. RCI also reduced levels of desmin and fibrosis-associated collagen deposition staining. Methylprednisolone did not improve renal function or pathology in this model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results provide evidence supporting the improvement of FSGS with RCI, which was superior to corticosteroid treatment in this experimental model. To the authors\u2019 knowledge, this is the first evidence that a drug for the treatment of FSGS supports podocyte recovery after repeated injury.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-020-01879-6","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T13:03:52Z","timestamp":1592226232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model"],"prefix":"10.1186","volume":"21","author":[{"given":"Kyle","family":"Hayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"issue":"2","key":"1879_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1053\/j.ackd.2014.10.001","volume":"22","author":"L Malaga-Dieguez","year":"2015","unstructured":"Malaga-Dieguez L, Bouhassira D, Gipson D, Trachtman H. Novel therapies for FSGS: preclinical and clinical studies. Adv Chronic Kidney Dis. 2015;22(2):e1\u20136.","journal-title":"Adv Chronic Kidney Dis"},{"key":"1879_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.12688\/f1000research.10510.1","volume":"6","author":"V Peev","year":"2017","unstructured":"Peev V, Hahm E, Reiser J. Unwinding focal segmental glomerulosclerosis. F1000Res. 2017;6:466.","journal-title":"F1000Res"},{"key":"1879_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/IJNRD.S126844","volume":"10","author":"S Beaudreuil","year":"2017","unstructured":"Beaudreuil S, Lorenzo HK, Elias M, Nnang Obada E, Charpentier B, Durrbach A. Optimal management of primary focal segmental glomerulosclerosis in adults. Int J Nephrol Renovasc Dis. 2017;10:97\u2013107.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"5","key":"1879_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0272-6386(97)90485-6","volume":"30","author":"M Haas","year":"1997","unstructured":"Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997;30(5):621\u201331.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1879_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.mayocp.2017.10.021","volume":"93","author":"JJ Sim","year":"2018","unstructured":"Sim JJ, Bhandari SK, Batech M, Hever A, Harrison TN, Shu YH, et al. End-stage renal disease and mortality outcomes across different glomerulonephropathies in a large diverse US population. Mayo Clin Proc. 2018;93(2):167\u201378.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1879_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139\u2013274.","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"1879_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1523-1755.2004.00553.x","volume":"65","author":"S de Haij","year":"2004","unstructured":"de Haij S, Daha MR, van Kooten C. Mechanism of steroid action in renal epithelial cells. Kidney Int. 2004;65(5):1577\u201388.","journal-title":"Kidney Int"},{"issue":"5","key":"1879_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1053\/j.ackd.2014.03.016","volume":"21","author":"J Hogan","year":"2014","unstructured":"Hogan J, Radhakrishnan J. The treatment of idiopathic focal segmental glomerulosclerosis in adults. Adv Chronic Kidney Dis. 2014;21(5):434\u201341.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"Suppl 1","key":"1879_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000481632","volume":"47","author":"JA Tumlin","year":"2018","unstructured":"Tumlin JA, Campbell KN. Proteinuria in nephrotic syndrome: mechanistic and clinical considerations in optimizing management. Am J Nephrol. 2018;47(Suppl 1):1\u20132.","journal-title":"Am J Nephrol"},{"issue":"Suppl 1","key":"1879_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000481634","volume":"47","author":"KN Campbell","year":"2018","unstructured":"Campbell KN, Tumlin JA. Protecting podocytes: a key target for therapy of focal segmental glomerulosclerosis. Am J Nephrol. 2018;47(Suppl 1):14\u201329.","journal-title":"Am J Nephrol"},{"key":"1879_CR11","unstructured":"Acthar Gel. Package insert. Mallinckrodt ARD LLC; 2019."},{"issue":"5","key":"1879_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.ekir.2017.05.015","volume":"2","author":"J Tumlin","year":"2017","unstructured":"Tumlin J, Galphin C, Santos R, Rovin B. Safety and efficacy of combination ACTHar gel and tacrolimus in treatment-resistant focal segmental glomerulosclerosis and membranous glomerulopathy. Kidney Int Rep. 2017;2(5):924\u201332.","journal-title":"Kidney Int Rep"},{"key":"1879_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/DDDT.S17521","volume":"5","author":"AS Bomback","year":"2011","unstructured":"Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, Appel AS, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther. 2011;5:147\u201353.","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 1","key":"1879_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000481635","volume":"47","author":"AS Bomback","year":"2018","unstructured":"Bomback AS, Fervenza FC. Membranous nephropathy: approaches to treatment. Am J Nephrol. 2018;47(Suppl 1):30\u201342.","journal-title":"Am J Nephrol"},{"issue":"46","key":"1879_CR15","doi-asserted-by":"publisher","first-page":"18205","DOI":"10.1073\/pnas.0706953104","volume":"104","author":"D Chida","year":"2007","unstructured":"Chida D, Nakagawa S, Nagai S, Sagara H, Katsumata H, Imaki T, et al. Melanocortin 2 receptor is required for adrenal gland development, steroidogenesis, and neonatal gluconeogenesis. Proc Natl Acad Sci U S A. 2007;104(46):18205\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1879_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/cphy.c150015","volume":"6","author":"JP Herman","year":"2016","unstructured":"Herman JP, McKlveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. Regulation of the hypothalamic-pituitary-adrenocortical stress response. Compr Physiol. 2016;6(2):603\u201321.","journal-title":"Compr Physiol"},{"issue":"1","key":"1879_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.56.1.1","volume":"56","author":"A Catania","year":"2004","unstructured":"Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1\u201329.","journal-title":"Pharmacol Rev"},{"issue":"8","key":"1879_CR18","doi-asserted-by":"publisher","first-page":"E104","DOI":"10.3390\/brainsci7080104","volume":"7","author":"RP Lisak","year":"2017","unstructured":"Lisak RP, Benjamins JA. Melanocortins, melanocortin receptors and multiple sclerosis. Brain Sci. 2017;7(8):E104.","journal-title":"Brain Sci"},{"key":"1879_CR19","doi-asserted-by":"crossref","unstructured":"Lindskog A, Ebefors K, Johansson ME, Stef\u00e1nsson B, Granqvist A, Arnadottir M, et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol. 2010;21(8):1290\u20138.","DOI":"10.1681\/ASN.2009101025"},{"key":"1879_CR20","doi-asserted-by":"crossref","unstructured":"Lindskog Jonsson A, Granqvist A, Elvin J, Johansson ME, Haraldsson B, Nystr\u00f6m J. Effects of melanocortin 1 receptor agonists in experimental nephropathies. PLoS One. 2014;9(1):e87816.","DOI":"10.1371\/journal.pone.0087816"},{"key":"1879_CR21","doi-asserted-by":"crossref","unstructured":"Elvin J, Buvall L, Lindskog Jonsson A, Granqvist A, Lass\u00e9n E, Bergwall L, et al. Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation. Am J Physiol Renal Physiol. 2016;310(9):F846\u2013F56.","DOI":"10.1152\/ajprenal.00231.2015"},{"issue":"1","key":"1879_CR22","doi-asserted-by":"publisher","first-page":"15731","DOI":"10.1038\/s41598-018-34004-7","volume":"8","author":"L Bergwall","year":"2018","unstructured":"Bergwall L, Wallentin H, Elvin J, Liu P, Boi R, Sihlbom C, et al. Amplification of the melanocortin-1 receptor in nephrotic syndrome identifies a target for podocyte cytoskeleton stabilization. Sci Rep. 2018;8(1):15731.","journal-title":"Sci Rep"},{"issue":"2","key":"1879_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/jcph.582","volume":"56","author":"R Lal","year":"2016","unstructured":"Lal R, Bell S, Challenger R, Hammock V, Nyberg M, Decker D, et al. Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: a comparison with intravenous methylprednisolone. J Clin Pharmacol. 2016;56(2):195\u2013202.","journal-title":"J Clin Pharmacol"},{"key":"1879_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/IMCRJ.S104899","volume":"9","author":"EJ Filippone","year":"2016","unstructured":"Filippone EJ, Dopson SJ, Rivers DM, Monk RD, Udani SM, Jafari G, et al. Adrenocorticotropic hormone analog use for podocytopathies. Int Med Case Rep J. 2016;9:125\u201333.","journal-title":"Int Med Case Rep J"},{"issue":"2","key":"1879_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrneph.2011.190","volume":"8","author":"R Gong","year":"2011","unstructured":"Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol. 2011;8(2):122\u20138.","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"1879_CR26","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.2215\/CJN.02840313","volume":"8","author":"J Hogan","year":"2013","unstructured":"Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol. 2013;8(12):2072\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1879_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.matbio.2018.02.017","volume":"68\u201369","author":"M Allinovi","year":"2018","unstructured":"Allinovi M, De Chiara L, Angelotti ML, Becherucci F, Romagnani P. Anti-fibrotic treatments: a review of clinical evidence. Matrix Biol. 2018;68\u201369:333\u201354.","journal-title":"Matrix Biol"},{"issue":"2","key":"1879_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1053\/snep.2003.50015","volume":"23","author":"AB Fogo","year":"2003","unstructured":"Fogo AB. Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol. 2003;23(2):161\u201371.","journal-title":"Semin Nephrol"},{"key":"1879_CR29","doi-asserted-by":"crossref","unstructured":"Suzuki K, Fukusumi Y, Yamazaki M, Kaneko H, Tsuruga K, Tanaka H, et al. Alteration in the podoplanin\u2013ezrin\u2013cytoskeleton linkage is an important initiation event of the podocyte injury in puromycin aminonucleoside nephropathy, a mimic of minimal change nephrotic syndrome. Cell Tissue Res. 2015;362(1):201\u201313.","DOI":"10.1007\/s00441-015-2178-8"},{"issue":"1","key":"1879_CR30","doi-asserted-by":"publisher","first-page":"F81","DOI":"10.1152\/ajprenal.00349.2003","volume":"287","author":"A Erdely","year":"2004","unstructured":"Erdely A, Freshour G, Smith C, Engels K, Olson JL, Baylis C. Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat. Am J Physiol Renal Physiol. 2004;287(1):F81\u20139.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"1879_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4103\/0976-500X.119726","volume":"4","author":"J Charan","year":"2013","unstructured":"Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4(4):303\u20136.","journal-title":"J Pharmacol Pharmacother"},{"issue":"11","key":"1879_CR32","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1681\/ASN.2012040389","volume":"23","author":"SM Korbet","year":"2012","unstructured":"Korbet SM. Treatment of primary FSGS in adults. J Am Soc Nephrol. 2012;23(11):1769\u201376.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1879_CR33","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420\u20138.","journal-title":"J Clin Invest"},{"key":"1879_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12882-016-0241-7","volume":"17","author":"A Madan","year":"2016","unstructured":"Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. BMC Nephrol. 2016;17:37.","journal-title":"BMC Nephrol"},{"issue":"1","key":"1879_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/TP.0000000000002320","volume":"103","author":"T Alhamad","year":"2019","unstructured":"Alhamad T, Manllo Dieck J, Younus U, Matar D, Alasfar S, Vujjini V, et al. ACTH Gel in resistant focal segmental glomerulosclerosis after kidney transplantation. Transplantation. 2019;103(1):202\u20139.","journal-title":"Transplantation"},{"issue":"4","key":"1879_CR36","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.amjms.2017.12.019","volume":"355","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Jiang C, Tang T, Wang H, Xia Y, Shao Q, et al. Clinical significance of urinary biomarkers in patients with primary focal segmental glomerulosclerosis. Am J Med Sci. 2018;355(4):314\u201321.","journal-title":"Am J Med Sci"},{"issue":"5","key":"1879_CR37","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1681\/ASN.2007040486","volume":"19","author":"J Lorenzen","year":"2008","unstructured":"Lorenzen J, Shah R, Biser A, Staicu SA, Niranjan T, Garcia AM, et al. The role of osteopontin in the development of albuminuria. J Am Soc Nephrol. 2008;19(5):884\u201390.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1879_CR38","doi-asserted-by":"publisher","first-page":"F119","DOI":"10.1152\/ajprenal.00143.2010","volume":"300","author":"S Schordan","year":"2011","unstructured":"Schordan S, Schordan E, Endlich K, Endlich N. AlphaV-integrins mediate the mechanoprotective action of osteopontin in podocytes. Am J Physiol Renal Physiol. 2011;300(1):F119\u201332.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1879_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1146\/annurev.pharmtox.48.113006.094615","volume":"48","author":"VS Vaidya","year":"2008","unstructured":"Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol. 2008;48:463\u201393.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"1879_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13730-018-0330-5","volume":"7","author":"M Sugiyama","year":"2018","unstructured":"Sugiyama M. Measurement of urinary biomarkers in a case of tubulointerstitial nephritis and uveitis syndrome during glucocorticoid treatment. CEN Case Rep. 2018;7(2):221\u20134.","journal-title":"CEN Case Rep"},{"issue":"11","key":"1879_CR41","doi-asserted-by":"publisher","first-page":"F1375","DOI":"10.1152\/ajprenal.00020.2013","volume":"304","author":"J Zhang","year":"2013","unstructured":"Zhang J, Pippin JW, Krofft RD, Naito S, Liu ZH, Shankland SJ. Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. Am J Physiol Renal Physiol. 2013;304(11):F1375\u2013F89.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"1879_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","volume":"47","author":"C Ponticelli","year":"2006","unstructured":"Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis. 2006;47(2):233\u201340.","journal-title":"Am J Kidney Dis"},{"key":"1879_CR43","doi-asserted-by":"publisher","first-page":"27589","DOI":"10.1038\/srep27589","volume":"6","author":"Y Qiao","year":"2016","unstructured":"Qiao Y, Berg AL, Wang P, Ge Y, Quan S, Zhou S, et al. MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy. Sci Rep. 2016;6:27589.","journal-title":"Sci Rep"}],"updated-by":[{"DOI":"10.1186\/s12882-020-01933-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000}}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01879-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01879-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01879-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T23:32:40Z","timestamp":1626391960000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01879-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1879"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01879-6","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12882-020-01933-3","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All study procedures, including for animal use welfare, were in accordance with the National Institute of Health\u2019s Guide for the Care and Use of Laboratory Animals. The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee of Mallinckrodt Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All of the authors are employees of Mallinckrodt Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}